8-K: Xenetic Biosciences Reports Full Year 2024 Financial Results and Highlights DNase-Based Technology Advancements

Xenetic Biosciences announces its full year 2024 financial results, highlighting progress in DNase-based technology for cancer treatment and strategic collaborations.

Summary

• Xenetic Biosciences reported a net loss of approximately $4.0 million for the year ended December 31, 2024.
• Research and development expenses decreased by approximately $0.2 million, or 5.9%, to $3.3 million from $3.5 million in the prior year period, primarily due to decreased spending in connection with the Company's DNase process development efforts.
• Royalty payments from Takeda Pharmaceuticals were approximately $2.5 million, relatively flat compared to 2023.
• General and administrative expenses decreased by approximately $0.1 million, or 4.1%, to $3.4 million, mainly due to reduced legal and accounting costs.
• The company ended the year with approximately $6.2 million in cash.
• Xenetic is focused on advancing its DNase-based technology towards a Phase 1 clinical trial for pancreatic carcinoma and other solid tumors.
• Preliminary preclinical studies evaluating DNase I with chemotherapy and immunotherapies in colorectal cancer models, as well as CAR-T therapy, have been completed.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reported a net loss, it is making progress in its DNase-based technology and has strategic collaborations in place. The focus on future clinical trials is a positive sign, but the financial situation warrants caution.

Positives

• Xenetic Biosciences is advancing its DNase-based technology towards a Phase 1 clinical trial for pancreatic carcinoma and other solid tumors.
• The company has extended collaborations with the University of Virginia and Scripps Research through 2025.
• Xenetic entered into a Clinical Trial Services Agreement with PeriNess Ltd. to manage investigator-initiated exploratory studies of DNase I.
• The company continues to establish and present a growing body of preclinical data that supports the use of its DNase-based technology across several cancer indications.
• The company ended the year with approximately $6.2 million in cash.

Negatives

• Xenetic Biosciences reported a net loss of approximately $4.0 million for the year ended December 31, 2024.

Risks

• Unexpected costs, charges, or expenses resulting from manufacturing and collaboration agreements could adversely affect the company.
• Uncertainty regarding the expected financial performance of the company following the licensing of the DNase platform poses a risk.
• Failure to realize the anticipated potential of the DNase or PolyXen technologies could impact the company's prospects.
• The ability of the company to obtain funding and implement its business strategy is subject to various risks and uncertainties.
• General market factors, economic conditions, public health issues, and geopolitical events could adversely affect the company's performance.

Future Outlook

Xenetic is focused on advancing its DNase-based technology towards a Phase 1 clinical trial for pancreatic carcinoma and other locally advanced or metastatic solid tumors, with plans to execute on initiatives and progress towards an IND.

Management Comments

• Looking ahead to 2025, we are executing on our initiatives as we progress toward an IND and Phase 1 clinical trial and look forward to an exciting year, commented James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic.

Industry Context

Xenetic Biosciences is operating in the competitive immuno-oncology space, focusing on novel approaches like DNase technology to improve cancer treatment outcomes, particularly in difficult-to-treat cancers like pancreatic carcinoma. The company's strategy of partnering with institutions and leveraging investigator-initiated studies is a common approach for smaller biopharmaceutical companies to advance their technologies efficiently.

Comparison to Industry Standards

• Xenetic's focus on DNase technology targeting NETs is a unique approach compared to more common immuno-oncology targets like PD-1/PD-L1 or CAR-T therapies.
• The company's reliance on collaborations and investigator-initiated studies is similar to other small biotech companies like OncoSec Medical Incorporated, which also leverages partnerships to advance its pipeline.
• The $6.2 million cash position is relatively low for a company entering Phase 1 clinical trials, suggesting a potential need for future capital raises.
• Compared to larger pharmaceutical companies like Roche or Novartis, which have extensive internal R&D capabilities, Xenetic's strategy is more resource-constrained and dependent on external collaborations.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and progress in DNase technology development will impact shareholder value.
• Employees: The company's strategic focus and clinical trial plans will affect employee roles and opportunities.
• Patients: Advancements in DNase technology could potentially lead to new treatment options for difficult-to-treat cancers.
• Partners: Collaborations with universities and PeriNess Ltd. will impact the progress of DNase technology development.

Next Steps

• Progressing towards an IND and Phase 1 clinical trial for DNase-based technology.
• Advancing the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other solid tumors.
• Continuing strategic collaborations to advance the company's technology.

Key Dates